bioRxiv Preprint Server
July 23, 2025
Tomas Del Olmo, Mathilde Decourcelle, Martial Séveno et al.
preprint
The serotonin (5-HT)2A receptor is the primary target of numerous psychoactive drugs including serotonergic psychedelics, and mediates psychedelics-induced neuroplasticity, but the signaling mechanisms involved remain poorly characterized. Using quantitative phosphoproteomics, we show that the administration of the hallucinogenic 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) to...
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
March 1, 2024
Mehdi Sekssaoui, Joël Bockaert, Philippe Marin et al.
76 citations
Major depressive disorder (MDD) is one of the most disabling psychiatric disorders in the world. First-line treatments such as selective serotonin reuptake inhibitors (SSRIs) still have many limitations, including a resistance to treatment in 30% of patients and a delayed clinical benefit that is observed only after several weeks of treatment. Increasing clinical evidence indicates that the...
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
June 1, 2022
Błażej D. Pędzich, Sarah Rubens, Mehdi Sekssaoui et al.
Psychedelic-assisted psychotherapy gained considerable interest as a novel treatment strategy for fear-related mental disorders but the underlying mechanism remains poorly understood. The serotonin 2A (5-HT2A) receptor is a key target underlying the effects of psychedelics on emotional arousal but its role in fear processing remains controversial. Using the psychedelic 5-HT2A/5-HT2C receptor...
Molecular & Cellular Proteomics
March 18, 2014
Samah Karaki, Carine Bécamel, Samy Murat et al.
73 citations
The serotonin 5-HT(2A) receptor is a primary target of psychedelic hallucinogens such as lysergic acid diethylamine, mescaline, and psilocybin, which reproduce some of the core symptoms of schizophrenia. An incompletely resolved paradox is that only some 5-HT(2A) receptor agonists exhibit hallucinogenic activity, whereas structurally related agonists with comparable affinity and activity lack...
Proceedings of the National Academy of Sciences of the United States of America
October 9, 2007
Alexandra Jean, Grégory Conductier, Christine Manrique et al.
Anorexia nervosa is a growing concern in mental health, often inducing death. The potential neuronal deficits that may underlie abnormal inhibitions of food intake, however, remain largely unexplored. We hypothesized that anorexia may involve altered signaling events within the nucleus accumbens (NAc), a brain structure involved in reward. We show here that direct stimulation of serotonin...
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
June 2005
Grégory Conductier, Cyril Crosson, René Hen et al.
3,4-Methylenedioxy-N-methamphetamine (MDMA or 'ecstasy') is a psychoactive substance, first described as an appetite suppressant in humans, inducing side effects and even death. MDMA increases serotonin (5-HT) levels, and 5-HT inhibits food intake, but the 5-HT receptors involved in MDMA-induced changes in feeding behavior are unknown. We examined whether a systemic MDMA injection would reduce...